Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke

NCT04890366 is registered in ClinicalTrials.gov with Xuanwu Hospital, Beijing as lead sponsor.

NCT NCT04890366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04890366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke
Lead sponsor
Xuanwu Hospital, Beijing
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 1, 2021
Completion date
December 31, 2022
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke